Q4 2024 Results Conference Call March 19, 2025 8:30 AM ETCompany ParticipantsDan Ferry - IR, LifeSci AdvisorsOfer Gonen - ...

Investment analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of MediWound in a research ...

MediWound (NASDAQ:MDWD – Get Free Report) was upgraded by analysts at StockNews.com to a “sell” rating in a report issued on Friday. Other research analysts have also issued reports about the company.

Reported positive results from the Expanded Access Protocol (NEXT), reinforcing NexoBrid's clinical and real-world benefits across 29 burn centers in the U.S. The study included 239 patients (215 ...

MediWound Ltd (NASDAQ: MDWD) reported its fourth-quarter 2024 earnings, showcasing a better-than-expected performance with an EPS of -0.36, surpassing the forecasted -0.56. Revenue for the quarter ...

These 12 undervalued financial-services stocks look attractive today. We sell different types of products and services to both investment professionals and individual investors. These products and ...

MediWound Ltd (NASDAQ: MDWD) reported its fourth-quarter 2024 earnings, showcasing a better-than-expected performance with an EPS of -0.36, surpassing the forecasted -0.56. Revenue for the quarter ...

Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for ...